Search research articles
Contact Us
Filters
Showing results (371-380 of 426) with videos related to
Page
of 43
Sort By:
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The Lancet. Oncology
|
October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
Iscience
|
December 24, 2025
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
Daniel Westaby, Juan M Jiménez-Vacas, Ines Figueiredo, et al.
European Urology
|
June 9, 2021
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
Semini Sumanasuriya, George Seed, Harry Parr, et al.
European Urology
|
December 21, 2017
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
Jun Luo, Gerhardt Attard, Steven P Balk, et al.
Prostate Cancer and Prostatic Diseases
|
August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study
Julie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
M P Kolinsky, P Rescigno, D Bianchini, et al.
JNCI Cancer Spectrum
|
April 25, 2020
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
Sarina A Piha-Paul, Christine L Hann, Christopher A French, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2001
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group
K Fizazi, S Tjulandin, R Salvioni, et al.
European Urology
|
August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
Alex P Hoyle, Adnan Ali, Nicholas D James, et al.
Page
of 43
Search research articles
Search
Showing results (371-380 of 426) with videos related to
Sort By:
Page
of 43
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The Lancet. Oncology
|
October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
Iscience
|
December 24, 2025
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
Daniel Westaby, Juan M Jiménez-Vacas, Ines Figueiredo, et al.
European Urology
|
June 9, 2021
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
Semini Sumanasuriya, George Seed, Harry Parr, et al.
European Urology
|
December 21, 2017
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
Jun Luo, Gerhardt Attard, Steven P Balk, et al.
Prostate Cancer and Prostatic Diseases
|
August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study
Julie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
M P Kolinsky, P Rescigno, D Bianchini, et al.
JNCI Cancer Spectrum
|
April 25, 2020
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
Sarina A Piha-Paul, Christine L Hann, Christopher A French, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2001
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group
K Fizazi, S Tjulandin, R Salvioni, et al.
European Urology
|
August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
Alex P Hoyle, Adnan Ali, Nicholas D James, et al.
Page
of 43